Solexa Limited has completed its previously announced merger with Lynx Therapeutics, and will follow the deal with the release of a multi-faceted gene-analysis platform later this year, the new company announced this week.

The new entity, to be called Solexa, said that it had incorporated itself in the US as Solexa, Inc., and that Solexa Ltd. has become its wholly owned UK subsidiary. The company received approval for listing on the Nasdaq SmallCap Market and began trading March 7 under the ticker symbol SLXA.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.